Back

Glucose-to-potassium ratio independently predicts long-term adverse outcomes in patients with coronary artery disease after PCI

28 August 2026 (15:15 - 16:00)
Organised by: Logo
Congress Presentation Part of: Biological determinants of atherosclerosis Biomarkers ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Kexin Zhang

Beijing (China)

4 More presentations in this session

Presentation thumbnail
Polygenic risk score is associated with high-risk plaque and coronary plaque burden in patients with non-obstructive coronary artery disease
Ms E. Gaillard (Amsterdam, NL)
Abstract Slides
Presentation thumbnail
Olink proteomic inflammatory biomarkers enhance precision risk prediction for long-term outcomes in coronary artery disease
Miss K. Zhang (Beijing, CN)
Abstract Slides
Presentation thumbnail
Genetic determinants of coronary resilience: why do some high-risk individuals escape coronary artery disease?
Doctor F. Sousa (Funchal, PT)
Abstract Slides
Presentation thumbnail
Coronary artery calcium predicts 5-year all-cause-, non-cardiovascular-, and cancer mortality
Professor J. Anderson (Murray, US)
Abstract Slides

Access the full session

Session thumbnail
Biological determinants of atherosclerosis

The Event

Event poster

ESC Congress 2026

28 August 2026 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Outcome predictors in acute coronary syndrome in patients submitted to percutaneous coronary intervention
15 March 2025
thumbnail
Congress Presentation
Insulin resistance assessed by estimated glucose disposal rate predicts cardiovascular disease in early-stage cardiovascular-kidney-metabolic syndrome: a prospective cohort study
1 September 2025
thumbnail
Congress Presentation
The impact of the glucose-potassium ratio on the 1-year prognosis in patients with HFpEF
20 May 2025
thumbnail
Congress Presentation
High levels of small dense LDL cholesterol potentiate the risk of poor glycemic management for long-term prognosis in patients with stable coronary artery disease
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources